Showing results (51-60 of 58) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2013
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancerAlberto Chiappori, Charles Williams, Donald W Northfelt, et al.Oncotarget|July 10, 2015
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsDavid S Hong, Peter Rosen, A Craig Lockhart, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL studyNathan Fowler, Brad S Kahl, Peter Lee, et al.Annals of Emergency Medicine|September 4, 2007
The Tuscan Emergency Medicine InitiativeKevin M Ban, Ricardo Pini, Leon D Sanchez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancersDaniel D Von Hoff, Joseph J Stephenson, Peter Rosen, et al.Cancer|December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerWalter M Stadler, David J Vaughn, Guru Sonpavde, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell LymphomaKevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.Blood|May 5, 2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaRavi Vij, Michael Wang, Jonathan L Kaufman, et al.Pageof 6